Recruiting PHASE2 INTERVENTIONAL 2-arm NCT07070700

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-02)

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-02): A Single-arm, Multi-cohort, Phase 2 Trial

Sponsor: Fudan University

Conditions Intrahepatic Cholangiocarcinoma (Icc)

Interventions Lenvatinib QL1706 (bispecific antibody targeting PD-1 and CLTA-4) cryoablation

Updated 2 times since 2025 Last updated: Aug 10, 2025 Started: Aug 20, 2025 Primary completion: Aug 1, 2027 Completion: Aug 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Intrahepatic Cholangiocarcinoma (Icc) and is currently actively recruiting participants. Fudan University leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Aug 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China